UPC Update - The new CMS is online
On July 8, the UPC has launched the first phase of its new CMS-rollout. Starting with limited functional scope, the new CMS is set to become fully operational in September.
G 1/23: No “Enablement” Hurdle for Prior Art Products Put on the Market – EPO Clarifies Scope of Prior Art
Enlarged Board of Appeal confirms: Commercially available products are prior art, even if they are not fully analyzable or reproducible
How the EPO addresses public prior use in clinical trials and patentability obstacles for pharmaceutical inventions
This article explores how the European Patent Office (EPO) addresses public prior use in the context of clinical trials.
IP strategies for the second funding round
As you scale, investors are looking at more than the potential of your IP, says Mathias Karlhuber. They now want to know whether it can support future growth and withstand any attacks.
G1/24: EPO’s Game-Changing Patent Claim Interpretation Ruling
EPO Moves Toward Harmonization with UPC and German Courts
Ready for the digital world? The new European design law
An overview of the most important changes and their significance in practice
EPO study finds technology standards secure economic growth
C&F: “Good times for standard essential patents”
UPC Decision Sets Precedent for Life Sciences Patents
Local Division Düsseldorf Issues Landmark Ruling on Second Medical Use Claims in Sanofi v. Amgen
Our expertise
We’ll support you with the development, registration, and pursuit of your intellectual property rights (IP). Moreover, we’ll advise you strategically on the systematic set-up, management, and maintenance of a patent portfolio, the design of IP management for your operation, and due-diligence processes. We’ll represent you in all matters relating to intellectual property rights and associated areas of law before courts and authorities. This includes defending and enforcing your intellectual property right.
